In silico identification of bilobetin and ginsenoside as dual CK2 and ULK2 inhibitors targeting triple-negative breast cancer.
- DOI
- 10.1038/s41598-025-33464-y
- Published
- 2025 Dec 30
- Container
- Scientific reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-025-33464-y,
title = {In silico identification of bilobetin and ginsenoside as dual CK2 and ULK2 inhibitors targeting triple-negative breast cancer.},
author = {Hossain MA and Tamanna IJ and Hossain MS and Parvez A and Afrin S and Sobuj DR and Islam MT and Al Noman A and Ahmed M and Sultana S and Srivastava S and Rao GSNK and Khan SR and Babu MR and Tariq M and Saiyad MT and Hamzah Z and Jain M},
year = {2025},
journal = {Scientific reports},
doi = {10.1038/s41598-025-33464-y},
url = {https://doi.org/10.1038/s41598-025-33464-y}
}RIS
TY - JOUR TI - In silico identification of bilobetin and ginsenoside as dual CK2 and ULK2 inhibitors targeting triple-negative breast cancer. AU - Hossain MA AU - Tamanna IJ AU - Hossain MS AU - Parvez A AU - Afrin S AU - Sobuj DR AU - Islam MT AU - Al Noman A AU - Ahmed M AU - Sultana S AU - Srivastava S AU - Rao GSNK AU - Khan SR AU - Babu MR AU - Tariq M AU - Saiyad MT AU - Hamzah Z AU - Jain M PY - 2025 JO - Scientific reports DO - 10.1038/s41598-025-33464-y UR - https://doi.org/10.1038/s41598-025-33464-y ER -
APA
MA, H., IJ, T., MS, H., A, P., S, A., DR, S., MT, I., A, A. N., M, A., S, S., S, S., GSNK, R., SR, K., MR, B., M, T., MT, S., Z, H., & M, J. (2025). In silico identification of bilobetin and ginsenoside as dual CK2 and ULK2 inhibitors targeting triple-negative breast cancer.. Scientific reports. https://doi.org/10.1038/s41598-025-33464-y
Source records
- pubmed · retrieved 2026-09-26T00:58:39.770Z